

**VAERS Table of Reportable Events Following Vaccination\***

Vaccine/Toxoid	Event and interval** from vaccination
Tetanus in any combination; DTaP, DTP, DTP-Hib, DT, Td, TT, Tdap, DTaP-IPV, DTaP-IPV/Hib, DTaP-HepB-IPV	<ul style="list-style-type: none"> <li>A. Anaphylaxis or anaphylactic shock (7 days)</li> <li>B. Brachial neuritis (28 days)</li> <li>C. Shoulder Injury Related to Vaccine Administration (7 days)</li> <li>D. Vasovagal syncope (7 days)</li> <li>E. Any acute complications or sequelae (including death) of above events (interval - not applicable)</li> <li>F. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)</li> </ul>
Pertussis in any combination; DTaP, DTP, DTP-Hib, Tdap, DTaP-IPV, DTaP-IPV/Hib, DTaP-HepB-IPV	<ul style="list-style-type: none"> <li>A. Anaphylaxis or anaphylactic shock (7 days)</li> <li>B. Encephalopathy or encephalitis (7 days)</li> <li>C. Shoulder Injury Related to Vaccine Administration (7 days)</li> <li>D. Vasovagal syncope (7 days)</li> <li>E. Any acute complications or sequelae (including death) of above events (interval - not applicable)</li> <li>F. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)</li> </ul>
Measles, mumps and rubella in any combination; MMR, MMRV, MM	<ul style="list-style-type: none"> <li>A. Anaphylaxis or anaphylactic shock (7 days)</li> <li>B. Encephalopathy or encephalitis (15 days)</li> <li>C. Shoulder Injury Related to Vaccine Administration (7 days)</li> <li>D. Vasovagal syncope (7 days)</li> <li>E. Any acute complications or sequelae (including death) of above events (interval - not applicable)</li> <li>F. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)</li> </ul>
Rubella in any combination; MMR, MMRV	<ul style="list-style-type: none"> <li>A. Chronic arthritis (42 days)</li> <li>B. Any acute complications or sequelae (including death) of above event (interval - not applicable)</li> <li>C. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)</li> </ul>
Measles in any combination; MMR, MMRV, MM	<ul style="list-style-type: none"> <li>A. Thrombocytopenic purpura (7-30 days)</li> <li>B. Vaccine-strain measles viral infection in an immunodeficient recipient                             <ul style="list-style-type: none"> <li>o Vaccine-strain virus identified (interval - not applicable)</li> <li>o If strain determination is not done or if laboratory testing is inconclusive (12 months)</li> </ul> </li> <li>C. Any acute complications or sequelae (including</li> </ul>

**VAERS Table of Reportable Events Following Vaccination\***

Vaccine/Toxoid	Event and interval** from vaccination
	death) of above events (interval - not applicable) D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)
Oral Polio (OPV)	A. Paralytic polio <ul style="list-style-type: none"> <li>o in a non-immunodeficient recipient (30 days)</li> <li>o in an immunodeficient recipient (6 months)</li> <li>o in a vaccine-associated community case (interval - not applicable)</li> </ul> B. Vaccine-strain polio viral infection <ul style="list-style-type: none"> <li>o in a non-immunodeficient recipient (30 days)</li> <li>o in an immunodeficient recipient (6 months)</li> <li>o in a vaccine-associated community case (interval - not applicable)</li> </ul> C. Any acute complication or sequelae (including death) of above events (interval - not applicable) D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)
Inactivated Polio in any combination-IPV, DTaP-IPV, DTaP-IPV/Hib, DTaP-HepB-IPV	A. Anaphylaxis or anaphylactic shock (7 days) B. Shoulder Injury Related to Vaccine Administration (7 days) C. Vasovagal syncope (7 days) D. Any acute complication or sequelae (including death) of the above event (interval - not applicable) E. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)
Hepatitis B in any combination- HepB, HepA-HepB, DTaP-HepB-IPV, Hib-HepB	A. Anaphylaxis or anaphylactic shock (7 days) B. Shoulder Injury Related to Vaccine Administration (7 days) C. Vasovagal syncope (7 days) D. Any acute complications or sequelae (including death) of the above event (interval - not applicable) E. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)
<i>Haemophilus influenzae</i> type b in any combination (conjugate)- Hib, Hib-HepB, DTaP-IPV/Hib, Hib-MenCY	A. Shoulder Injury Related to Vaccine Administration (7 days) B. Vasovagal syncope (7 days) C. Any acute complication or sequelae (including death) of above events (interval - not applicable) D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine

<b>VAERS Table of Reportable Events Following Vaccination*</b>	
<b>Vaccine/Toxoid</b>	<b>Event and interval** from vaccination</b>
	(interval - see package insert)
Varicella in any combination- VAR, MMRV	<ul style="list-style-type: none"> <li>A. Anaphylaxis or anaphylactic shock (7 days)</li> <li>B. Disseminated varicella vaccine-strain viral disease. <ul style="list-style-type: none"> <li>o Vaccine-strain virus identified (time interval unlimited)</li> <li>o If strain determination is not done or if laboratory testing is inconclusive (42 days)</li> </ul> </li> <li>C. Varicella vaccine-strain viral reactivation (time interval unlimited )</li> <li>D. Shoulder Injury Related to Vaccine Administration (7 days)</li> <li>E. Vasovagal syncope (7 days)</li> <li>F. Any acute complication or sequelae (including death) of above events (interval - not applicable)</li> <li>G. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)</li> </ul>
Rotavirus (monovalent or pentavalent) RV1, RV5	<ul style="list-style-type: none"> <li>A. Intussusception (21 days)</li> <li>B. Any acute complication or sequelae (including death) of above events (interval - not applicable)</li> <li>C. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)</li> </ul>
Pneumococcal conjugate(7-valent or 13-valent) PCV7, PCV13	<ul style="list-style-type: none"> <li>A. Shoulder Injury Related to Vaccine Administration (7 days)</li> <li>B. Vasovagal syncope (7 days)</li> <li>C. Any acute complication or sequelae (including death) of above events (interval - not applicable)</li> <li>D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)</li> </ul>
Hepatitis A in any combination- HepA, HepA-HepB	<ul style="list-style-type: none"> <li>A. Shoulder Injury Related to Vaccine Administration (7 days)</li> <li>B. Vasovagal syncope (7 days)</li> <li>C. Any acute complication or sequelae (including death) of above events (interval - not applicable)</li> <li>D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)</li> </ul>
Seasonal influenza--trivalent inactivated influenza, quadrivalent inactivated influenza, live attenuated	<ul style="list-style-type: none"> <li>A. Anaphylaxis or anaphylactic shock (7 days)</li> <li>B. Shoulder Injury Related to Vaccine Administration (7 days)</li> <li>C. Vasovagal syncope (7 days)</li> </ul>

**VAERS Table of Reportable Events Following Vaccination\***

Vaccine/Toxoid	Event and interval** from vaccination
influenza-IIV, IIV3, IIV4, RIV3, ccIIV3, LAIV4	<ul style="list-style-type: none"> <li>D. Guillain-Barré Syndrome (42 days)</li> <li>E. Any acute complication or sequelae (including death) of above events (interval - not applicable)</li> <li>F. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)</li> </ul>
Meningococcal - MCV4, MPSV4, Hib-MenCY, MenACWY, MenB	<ul style="list-style-type: none"> <li>A. Anaphylaxis or anaphylactic shock (7 days)</li> <li>B. Shoulder Injury Related to Vaccine Administration. (7 days)</li> <li>C. Vasovagal syncope (7 days)</li> <li>D. Any acute complication or sequelae (including death) of above events (interval - not applicable)</li> <li>E. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)</li> </ul>
Human Papillomavirus (Quadrivalent, Bivalent, or 9 valent) - 9vHPV, 4vHPV, 2vHPV	<ul style="list-style-type: none"> <li>A. Anaphylaxis or anaphylactic shock (7days)</li> <li>B. Shoulder Injury Related to Vaccine Administration (7 days)</li> <li>C. Vasovagal syncope (7 days)</li> <li>D. Any acute complication or sequelae (including death) of above events (interval - not applicable)</li> <li>E. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)</li> </ul>
Any new vaccine recommended by the Centers for Disease Control and Prevention for routine administration to children	<ul style="list-style-type: none"> <li>A. Shoulder Injury Related to Vaccine Administration (7 days)</li> <li>B. Vasovagal syncope (7 days)</li> <li>C. Any acute complication or sequelae (including death) of above events (interval - not applicable)</li> <li>D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)</li> </ul>

\* Effective date: March 21, 2017. The Reportable Events Table (RET) reflects what is reportable by law (42 USC 300aa-25) to the Vaccine Adverse Event Reporting System (VAERS) including conditions found in the manufacturer package insert. In addition, healthcare professionals are encouraged to report any clinically significant or unexpected events (even if not certain the vaccine caused the event) for any vaccine, whether or not it is listed on the RET. Manufacturers are also required by regulation (21CFR 600.80) to report to the VAERS program all adverse events made known to them for any vaccine.

Note that the RET differs from the Vaccine Injury Table (VIT) regarding timeframes of adverse events. Timeframes listed on the RET reflect what is required for reporting, but not what is required for compensation. To view timeframes for compensation, please see the VIT at

<b>VAERS Table of Reportable Events Following Vaccination*</b>	
<b>Vaccine/Toxoid</b>	<b>Event and interval** from vaccination</b>
<p><b><a href="https://www.hrsa.gov/vaccinecompensation/vaccineinjurytable.pdf">https://www.hrsa.gov/vaccinecompensation/vaccineinjurytable.pdf</a></b></p> <p>**Represents the onset interval between vaccination and the adverse event.            For a detailed explanation of terms, see the Vaccine Injury Table at  <b><a href="https://www.hrsa.gov/vaccinecompensation/vaccineinjurytable.pdf">https://www.hrsa.gov/vaccinecompensation/vaccineinjurytable.pdf</a></b></p>	

A list of vaccine abbreviations is located at: <https://www.cdc.gov/vaccines/terms/vacc-abbrev.html>